pathological tumour stage (HR = 3.77; p = 0.020) and lymph node stage (HR = 2.34; p = 0.022) were significantly correlated with CSS. Conclusion: While the outcome of secondary MIBC is not generally adverse compared to primary MIBC, the EORTC risk score not only reflects high risk of progression of NMIBC to MIBC, but also worse outcome following RC for secondary MIBC. Timely RC should thus be debated in highrisk NMIBC.
Bladder cancer is the fourth most common cancer in men with severe impact on general health; it is generally divided into non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) [1] . Current guidelines recommend radical cystectomy (RC) with bilateral pelvic lymphadenectomy in MIBC and in NMIBC with high risk of progression [2, 3] . Risk of progression to MIBC is usually determined by the EORTC risk score combining various clinicopathological parameters [2] [3] [4] . Risk of cancer-specific mortality following RC for MIBC is usually determined by pathologi-cal tumour stage and lymph node status. Since cancerspecific survival (CSS) rates vary widely, other prognostic factors have been evaluated [5, 6] .
Progression of NMIBC to secondary MIBC, i.e. subsequent to preceding NMIBC as opposed to primary MIBC, could be a potential prognosticator conveying favourable outcome due to the initial non-muscle-invasive character of the bladder cancer or likewise a potential prognosticator conveying adverse outcome due to its progressive tumour biology.
The EORTC risk score predicting progression of NMIBC to MIBC could also be a potential prognosticator conveying adverse outcome by again reflecting progressive tumour biology. Should this scenario be true, debate of timely RC should be emphasized in the management of high-risk NMIBC and such debate should be based on EORTC risk scores. No conclusive data are available to date.
Currently, indications for RC for bladder cancer stages <pT2 are an issue of debate. While long-term bladder preservation is pursued for quality of life reasons, a tendency to advocate RC in case of BCG-refractory and initially recurrent T1 tumour stage is notable in the recent literature, since favourable long-term outcome has been suggested for timely radical treatment [7] [8] [9] [10] [11] . Due to prognostic uncertainty however the clinical management of high-risk NMIBC is demanding and any further prognosticator valuable. We presently analyse CSS in a current series of RC for primary compared to secondary MIBC to assess prognostic differences and analyse CSS in relation to EORTC risk score at the last transurethral resection of bladder tumour (TURBT) for NMIBC. No such data have been reported to date.
Materials and Methods

Patient Selection
Clinical and histopathological data of consecutive patients undergoing RC for clinically localized MIBC between 2004 and 2010 at one tertiary urological centre without neoadjuvant chemotherapy were collected. Figure 1 shows the stratification of the patients into different risk groups. Patients were subdivided into two groups: patients with primary MIBC (group 1) and patients with secondary MIBC (group 2). In order to preserve homogenous patient groups we excluded patients with secondary MIBC, if no intravesical BCG therapy had been performed (n = 11) or no re-resection at the time of T1 stage and/or CIS had been performed (n = 3). In secondary MIBC, EORTC risk scores at the time of the last TURBT for NMIBC were assessed, resulting in a score from 0 to 23 [4] : (a) number of tumours (single: 0, multiple: 3); (b) tumour size (<3 cm: 0, ≥ 3 cm: 3); (c) prior recurrence rate (primary: 0, recurrent: 2); (d) T category (cTa: 0, cT1: 4); (e) presence of concomitant CIS (no: 0, yes: 6); (f) grade (G1-2: 0, G3: 5). Subsequently, we devised different risk groups, as reported by Sylvester et al. [3] . Due to the frequent occurrence of high-risk patients we subdivided the high-risk group: (a) low-risk group: score <2; (b) intermediate-risk group: score 2-6; (c) high-risk group A: score 7-13; (d) high-risk group B: score 14-23. Time from diagnosis of MIBC to RC and from initial TURBT for NMIBC to RC was dichotomised at 90 days in accordance with previous reports [12] [13] [14] .
Pathological Evaluation
Surgical specimens were processed according to standard institutional protocols. Tumour grading and staging was performed by genitourinary pathologists according to the 1973 World Health Organization (WHO) grading system and the American Joint Committee on Cancer (AJCC)-Union Internationale Contre le Cancer tumour, nodes, metastasis (TNM) classification, respectively [15, 16] .
Follow-Up Regimen
Patients were followed according to institutional guidelines effective at that time largely reflecting current guidelines [2] . For the first and from the second through the fifth year after RC, follow-up visits were scheduled every 3 and 6 months, respectively, and annually thereafter with routine laboratory, ultrasound, urinary cytology, chest radiography, radiographic evaluation of the upper urinary tract and cystoscopic evaluation of the neobladder. Bone scan, computed tomography and/or magnetic resonance imagings were performed when clinically indicated. Cause of death was determined by the treating physician and death certificates.
Statistical Analysis
The hypothesis of normality for all continuous variables was tested by the Shapiro-Wilk normality test. Means and standard deviations were displayed for the continuous stable distributed variables. Medians with interquartile ranges (IQRs) were used to 
Oncological Outcome
The median follow-up was 46 months (IQR 31-62). In the entire population, CSS after 1, 3 and 5 years were 83, 67 and 59%, respectively. Pathological tumour stage pT3/4 (HR = 3.77; p = 0.020) and lymph node metastasis (HR = 2.34; p = 0.022) were independently associated with CSS in multivariate analysis ( table 2 ) . CSS did not differ significantly between primary and secondary MIBC (p = 0.521; fig. 2 ). Patients with secondary MIBC classified as high-risk A of progression at the last TURBT for NMIBC (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) showed significantly worse CSS compared to intermediate-risk or high-risk B patients (p = 0.029 and p = 0.033; fig. 3 ). 
Discussion
Does Outcome of Primary and Secondary MIBC Differ?
No definitely conclusive data on survival rates after RC for secondary MIBC subsequent to preceding NMIBC compared to primary MIBC have been reported to date and the present literature is arbitrary. In 2002, Yiou et al. [17] compared 43 and 12 patients with primary and secondary MIBC, respectively, reporting no difference in survival. May et al. [18] compared 132 and 57 patients with primary and secondary MIBC, respectively, again finding no difference in outcome or any other clinicopathological parameter. While May at al.'s series was larger than the present one, it was assessed in retrospect from various institutions while the present series was assessed prospectively with homogeneous treatment pattern due to institutional guidelines of one centre. In analogy to the present analyses, those series found no differences in outcome between primary versus secondary MIBC [17, 18] . A more recent retrospective series by de Vries et al. [19] assessing 134 and 54 patients with primary and secondary MIBC, respectively, found comparable survival rates. The most recent series by Kotb et al. [20] analysed 1,150 patients from the Canadian Bladder Cancer Network containing 32% of patients with secondary MIBC. In this series, outcome of secondary MIBC was advantageous, as CSS at 5 years was 70% compared to 60% of primary MIBC. While age at MIBC was comparable, many other factors were adverse in primary MIBC, e.g. presence of preoperative hydronephrosis (20. In contrast to the present series no details on NMIBC prior to MIBC were available and according to the authors different approaches toward early cystectomy in each centre might have biased the results [20] .
In accordance with the former series and in contrast to the most recent analysis our data again do not suggest generally adverse outcome of either variation. No other factor biasing CSS was noted in the present series. The ratio of patients with secondary MIBC of all patients undergoing RC for MIBC in the present series was 25% and thus within the range of previous series (21.4 to 29.4%) [18] [19] [20] [21] [22] . No differences in e.g. tumours stage, lymph node status or use of adjuvant chemotherapy were noted. Thus the present homogeneous and well-controlled data, also including detailed information of NMIBC preceding MIBC, suggest comparable outcome for primary and secondary MIBC.
Does Risk of Progression of NMIBC Matter for Outcome of Secondary MIBC?
Risk of progression does convey adverse tumour biology; accordingly the outcome of RC for high-risk NMIBC is still compromised in some cases despite radical tumour removal. Accordingly, risk of progression at time of last TURBT for NMIBC prior to MIBC could reflect outcome. To date, only one series assessed risk of progression; de Vries et al. [19] stratified 54 NMIBC in one low/intermediate-and one high-risk group (n = 25 and n = 29, respec- 
Which Conclusions Can Be Drawn for the Management of High-Risk NMIBC?
Outcome of secondary MIBC is generally critical; some 50% of the patients with cT2N0M0 had died from disease after 5 years. While this can be partly attributed to the high rate of upstaging to tumour stages ≥ pT3 and/or pN+, which is in accordance with the recent series by de Vries et al. and has been reported for up to 50% of all patients undergoing RC for MIBC [19, 22] , it stresses the need for close follow-up of NMIBC at risk of progression.
The present data furthermore demonstrate secondary MIBC subsequent to preceding NMIBC at high risk of progression to be brittle. Accordingly, debate of early RC should be considered previous to MIBC in high-risk NMIBC. This aspect is all the more challenging in the absence of reliable prognosticators of high-risk NMIBC. Recently, shortcomings of current grading systems for prognostic assessment were suggested [23] . Likewise, substaging of pT1 NMIBC in relation to depth of lamina propria invasion has been proposed due to inaccuracy of prognostic assessment [24, 25] . Molecular markers seem not to suffice in this regard and require further assessment [5, 26, 27] . Thus, the present data emphasize the use of the EORTC risk score of progression in high-risk NMIBC to gain some additional prognostic information.
Which Limitations of the Present Series Need to Be Taken into Account?
The present series is marked by several limitations. For one, the present dataset is small, containing but 25 patients with secondary MIBC. To date, no considerably larger dataset which is fairly homogeneous and well-controlled for biasing factors has been reported. Second, while the present data were assessed prospectively, EORTC risk scores were assigned retrospectively for the earlier years of the present series based on clinicopathological characteristics assessed at the time of TURBT. Third, while control for use of BCG therapy had been exerted in secondary MIBC, no exact control for number of doses and duration of therapy could be achieved. Fourth, no patient in the present series obtained neoadjuvant chemotherapy despite more recent respective recommendations [3] , which could compromise comparability to other data. 
Conclusions
Outcome of secondary MIBC subsequent to previous NMIBC is not generally adverse compared to primary MIBC. In high-risk NMIBC debate of early RC should be considered, since high EORTC risk scores of progression at the last TURBT for NMIBC convey poor prognosis not only for progression to MIBC but also for outcome of secondary MIBC following RC.
